-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,

new data to highlight strong activity against additional non-Type 1 mutations --

-- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) --

WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the acceptance of preclinical data highlighting the best-in-class potential of DMR-001 for poster presentation at the 2026 ASH Annual Meeting and Exposition. DMR-001 is an investigational pan-mutant, long-acting, Fc-null mutCALR therapy currently being evaluated as a potential treatment for patients with mutCALR-driven ET and MF in the CLARITY-101 Phase 1/1b clinical trial.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.